Literature DB >> 4364937

Susceptibility of herpesviruses to cytosine arabinoside: standardization of susceptibility test procedure and relative resistance of herpes simplex type 2 strains.

M Fiala, A Chow, L B Guze.   

Abstract

Susceptibility testing of herpes simplex type 1 (HSV-1) and type 2 (HSV-2) viruses to cytosine arabinoside (Ara-C) has been standardized under conditions of optimal reproducibility, susceptibility, and simplicity. Standard conditions were defined as virus inoculum of 10(1.5) to 10(2.5) TCID(50), WI-38 strain of lung fibroblasts, 2-day incubation, and observation of virus cytopathic effect after staining by the May-Greenwald-Giemsa method. The variability of minimum inhibitory concentration (MIC) of cytopathic effect was fourfold within each test and sixfold in successive assays. MIC values of all seven tested HSV-1 strains were in the range of 0.25 to 0.75 mug per ml, whereas four of nine HSV-2 strains had MIC values of 0.9 mug per ml and greater. A similar method can be used for assay of virus inhibitory titers of body fluids.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4364937      PMCID: PMC444221          DOI: 10.1128/AAC.1.4.354

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  CYTOSINE ARABINOSIDE (CA) AND OTHER NUCLEOSIDES IN HERPES VIRUS INFECTIONS.

Authors:  G E UNDERWOOD; C A WISNER; S D WEED
Journal:  Arch Ophthalmol       Date:  1964-10

2.  INHIBITION BY METABOLIC ANALOGUES OF PLAQUE FORMATION BY HERPES ZOSTER AND HERPES SIMPLEX VIRUSES.

Authors:  F RAPP
Journal:  J Immunol       Date:  1964-10       Impact factor: 5.422

3.  CELL CULTURE STUDIES ON ANTIVIRAL AGENTS. I. ACTION OF CYTOSINE ARABINOSIDE AND SOME COMPARISONS WITH 5-IODO-2-DEOXYURIDINE.

Authors:  D A BUTHALA
Journal:  Proc Soc Exp Biol Med       Date:  1964-01

4.  Cytosine arabinoside therapy for herpesvirus infections.

Authors:  A W Chow; J Foerster; W Hryniuk
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1970

5.  Investigation of plaque formation in chick embryo cells as a biological marker for distinguishing herpes virus type 2 from type 1.

Authors:  S P Lowry; J L Melnick; W E Rawls
Journal:  J Gen Virol       Date:  1971-01       Impact factor: 3.891

6.  Cytosine arabinoside therapy for disseminated herpes zoster in a patient with IgG pyroglobulinemia.

Authors:  E M McKelvey; H C Kwaan
Journal:  Blood       Date:  1969-11       Impact factor: 22.113

7.  Severe generalized primary herpes treated with cytarabine.

Authors:  B E Juel-Jensen
Journal:  Br Med J       Date:  1970-04-18

8.  In vitro determinations of viral susceptibility to drugs for possible clinical use.

Authors:  W E Walker; B A Waisbren; R R Martins; G E Batayias
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1970

9.  Influence of host cell on biologic markers of types 1 and 2. Herpesvirus hominis.

Authors:  K G Stubbs; M E Snider; C A Alford
Journal:  J Infect Dis       Date:  1971-02       Impact factor: 5.226

10.  Sensitivity of Types 1 and 2 Herpes Simplex Virus to 5-Iodo-2'-Deoxyuridine and 9-beta-d-Arabinofuranosyladenine.

Authors:  D A Person; P J Sheridan; E C Herrmann
Journal:  Infect Immun       Date:  1970-12       Impact factor: 3.441

View more
  13 in total

1.  Inhibition of herpes simplex virus replication by phosphonoacetic acid.

Authors:  L R Overby; E E Robishaw; J B Schleicher; A Rueter; N L Shipkowitz; J C Mao
Journal:  Antimicrob Agents Chemother       Date:  1974-09       Impact factor: 5.191

2.  Varicella-zoster virus and subcutaneous cytarabine: correlation of in vitro sensitivities to blood levels.

Authors:  D A Zaky; R F Betts; R G Douglas; K Bengali; G L Neil
Journal:  Antimicrob Agents Chemother       Date:  1975-03       Impact factor: 5.191

3.  Herpesvirus hominis infection in newborn mice: comparison of the therapeutic efficacy of 1-beta-D-arabinofuranosylcytosine and 9-beta-D-arabinofuranosyladenine.

Authors:  E R Kern; J C Overall; L A Glasgow
Journal:  Antimicrob Agents Chemother       Date:  1975-05       Impact factor: 5.191

Review 4.  The latent herpes simplex virus.

Authors:  J J Docherty; M Chopan
Journal:  Bacteriol Rev       Date:  1974-12

5.  A combined chemical-physical treatment for herpes simplex lesions in guinea pigs.

Authors:  T A Brawner; J E Senne; M Fahim
Journal:  Arch Dermatol Res       Date:  1979-05-29       Impact factor: 3.017

6.  Effect of cytosine arabinoside and 5-iodo-2'-deoxyuridine on a cytomegalovirus infection in newborn mice.

Authors:  D K Kelsey; E R Kern; J C Overall; L A Glasgow
Journal:  Antimicrob Agents Chemother       Date:  1976-03       Impact factor: 5.191

7.  Human cytomegalovirus. IV. Specific inhibition of virus-induced DNA polymerase activity and viral DNA replication by phosphonoacetic acid.

Authors:  E S Huang
Journal:  J Virol       Date:  1975-12       Impact factor: 5.103

8.  Assessment of cytosine arabinoside as an antiviral agent in humans.

Authors:  C B Lauter; E J Bailey; A M Lerner
Journal:  Antimicrob Agents Chemother       Date:  1974-11       Impact factor: 5.191

9.  Variables influencing the in vitro susceptibilities of herpes simplex viruses to antiviral drugs.

Authors:  M I Marks
Journal:  Antimicrob Agents Chemother       Date:  1974-07       Impact factor: 5.191

10.  Inactivation of Herpesvirus hominis types 1 and 2 by silver nitrate in vitro and in vivo.

Authors:  V R Coleman; J Wilkie; W E Levinson; T Stevens; E Jawetz
Journal:  Antimicrob Agents Chemother       Date:  1973-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.